Jun. 7, 2012 (China Knowledge) - Sanofi, a global and diversified healthcare leader, recently announced its launch of a new production line to produce Lantus SoloSTAR, a pre-filled insulin injection, in Beijing E-Town
Concurrently, it also launched its second phase of installation of a high-tech cartridge aseptic production line. With a designed annual output capacity of 48 million units, the added facility will help to meet the needs of China's diabetic patients.
In April 2009, Sanofi signed an agreement with Beijing E-Town
to set up a new assembly plant in the industrial park with a total investment of US$90 million.
Lantus is the most widely used insulin with about 47 million users worldwide. Except the Sanofi's Frankfurt plant, Beijing E-Town
has become the first Industrial production plant that can realize the local production of Lantus SoloSTAR pre-filled insulin injection.
At present, Sanofi has six production plants in China and its manufacturing facilities in Beijing E-Town
plant will become its high-end drug production base in the near future. During 12th five year plan period, between 2011 and 2015, Beijing E-Town
will focus on the development of its bioengineering and new medicine industry and aims to promote its contribution rate to over 60% in the capital, Sanofi's new production line will greatly aid Beijing E-Town
to achieve this target.